Benzinga | Jan 4, 2021 04:07PM EST

Exagen Inc. Partners with Oregon's St. Charles Health System to Offer AVISE Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

Exagen Inc. (NASDAQ:XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX, and HCQ) are a contracted in-network service with St. Charles Health System, the largest provider of medical care in Central Oregon.

"St. Charles has a far-reaching impact on the health and wellbeing of the communities they serve. As the largest employer in the region, providing access to AVISE testing will play an important part in enabling rheumatologists to improve patient care through the differential diagnosis, prognosis and monitoring of complex autoimmune diseases, including SLE," said Ron Rocca, President and CEO of Exagen.